Albireo Pharma Shares Plunge After Q2 Results Misses Profit Estimates

  • Albireo Pharma Inc ALBO reported second-quarter revenue of $8.21 million, with product revenue of $5.89 million, an increase of 238% year-over-year, beating the consensus of $7.45 million.
  • As of the end of Q2 2022, there are 245 total Bylvay patients—which include reimbursed, non-reimbursed, and rollover patients—representing +18% growth compared to Q1.
  • Bylvay reimbursement was confirmed in the U.S., Germany, United Kingdom, Italy, and Belgium.
  • EPS was $(2.04), which missed the consensus of $(1.65).
  • R&D expenses were $22.9 million, compared with $20.9 million in 2Q21.
  • The company had cash and cash equivalents of $181.0 million as of June 30, 2022.
  • Based on current revenue and expense projections, Albireo Pharma expects sufficient cash into 2024. Bylvay 2022 sales are now expected to be $24 million.
  • The company is On track to report topline data from the Phase 3 ASSERT study in Alagille syndrome (ALGS) this fall.
  • ALBO plans to initiate a Phase 1 first-in-human study for A2342 by the end of 2022. This will follow recently completed IND-enabling toxicology studies. A2342 is the first oral sodium-taurocholate co-transporting peptide (NTCP) inhibitor in development for hepatitis B and D.
  • Price Action: ALBO shares are trading lower by 16.20% at $20.90 during the post-market session on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsNewsSmall CapAfter-Hours CenterMoversTrading IdeasBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!